Newsroom.

- Submission for entering the world’s largest US marketplace

YONGIN, SOUTH KOREA, GC Biopharma (006280.KS) today announced that it had submitted its Biologics License Application (BLA) for 'GC5107 (Immune Globulin Intravenous (Human),10% Liquid) to the United States Food and Drug Administration (FDA).

GC Biopharma demonstrated positive results in a Phase III study in North America, meeting its primary efficacy endpoint of acute serious bacterial infections (SBI). In the trials included in the submission, with PI (Primary Humoral Immunodeficiency) patients, all primary efficacy and safety endpoints corresponding to FDA guidelines were satisfied.

In terms of efficacy, the frequency of SBI was 0.02 for 12 months, satisfying the FDA guidance requirement of no more than one acute serious bacterial infection per person-year. The proportion of infusions with one or more infusion-related AEs was less than 40%; therefore, the study also met its primary safety endpoint.

"The submission of the GC5107 represents a major step towards our ultimate goal of expanding our business to the US marketplace," said Eun Chul Huh, Ph. D., President of GC Biopharma. "GC5107 will provide meaningful treatment options to medical staffs and patients that further build on the success already achieved with our products in other parts of the world."

In general, the FDA has a 60-day filing review period to determine whether GC Biopharma' Biologics License Application for GC5107 is complete and acceptable for filing.

About GC Biopharma

GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company that delivers lifesaving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is one of the leading plasma protein and vaccine product manufacturers in the world and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updated its corporate brand to GC Biopharma in early 2018. Green Cross Corporation remains the company's legal name.

This press release may contain forward-looking statements that express GC Biopharma's and GC Biopharma USA, Inc.'s management's current beliefs and expectations. Such views do not represent any guarantee by either entity or its government of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma and GC Biopharma USA, Inc. undertake no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements they may make, except as required by law or stock exchange rule.